Microangiopathic hemolytic anemia: Difference between revisions

Jump to navigation Jump to search
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
No edit summary
Line 11: Line 11:
  | MeshID        =  
  | MeshID        =  
}}
}}
{{SI}}
{{Microangiopathic hemolytic anemia}}
{{CMG}}
{{CMG}}





Revision as of 14:00, 21 September 2012

Microangiopathic hemolytic anemia
ICD-10 D59.4
ICD-9 283.19
DiseasesDB 29721

Microangiopathic hemolytic anemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Microangiopathic hemolytic anemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Microangiopathic hemolytic anemia On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Microangiopathic hemolytic anemia

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Microangiopathic hemolytic anemia

on Microangiopathic hemolytic anemia

Microangiopathic hemolytic anemia in the news

Blogs on Microangiopathic hemolytic anemia

Directions to Hospitals Treating Microangiopathic hemolytic anemia

Risk calculators and risk factors for Microangiopathic hemolytic anemia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Overview

In medicine (hematology) microangiopathic hemolytic anemia (MAHA) is a subgroup of hemolytic anemia (anemia, loss of red blood cells through destruction) caused by factors in the small blood vessels. It is identified by the finding of anemia and schistocytes on microscopy of the blood film.

Presentation

In diseases such as hemolytic uremic syndrome, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, as well as malignant hypertension, the endothelial layer of small vessels are damaged with resulting fibrin deposition and platelet aggregation. As red blood cells travel through these damaged vessels, they are shredded. The result is red cell fragmentation and intravascular hemolysis. Under the microscope, damaged red cells have the appearance of schistocytes.

Automated analysers (the machines that perform routine full blood counts in most hospitals) are generally programmed to flag blood films that display red blood cell fragments or schistocytes.

Causes

The most important causes are:

Pathophysiology

In all causes, the mechanism of MAHA is the formation of a fibrin mesh due to increased activity of the system of coagulation. The red blood cells are physically cut by these protein networks, and the fragments are identical to the schistocytes seen on light microscopy.

Template:Hematology

Template:WikiDoc Sources